The reporting quality of randomized controlled trials in pharmacotherapy for pituitary adenomas

Hongmei Yan,Daiyan Wang,Yujing Zhao,Junjie Miao,Zhe Wang
DOI: https://doi.org/10.1097/md.0000000000037518
IF: 1.6
2024-03-17
Medicine
Abstract:Randomized controlled trials (RCTs) are considered the gold standard for evaluating interventions because of their ability to minimize or avoid bias. [ 1 , 2 ] Recent methodological analyses have indicated that insufficient reporting and design are associated with biased estimates of the treatment effects. Such systematic errors are seriously damaging to RCTs, and misleading readers and investigators not to judge the reliability and validity of trial findings or obtain information. [ 3 ] Critical appraisal of the quality of clinical trials is only possible if the design, conduct, and analysis of RCTs are thoroughly and accurately described in the report. Far from being transparent, RCT reporting is often incomplete, with compounding problems arising from poor methodologies. [ 3 , 4 ]
medicine, general & internal
What problem does this paper attempt to address?